GOP chairman: Drug prices ‘high on our agenda’

GOP chairman: Drug prices ‘high on our agenda’

Image result for high drug prices

House Energy and Commerce Committee Chairman Greg Walden (R-Ore.) said Tuesday that dealing with high drug prices will be “high on our agenda.”

The comments come after Walden attended a meeting at the White House earlier in the day with President Trump and the CEOs of several major drug companies, at which Trump pressed the companies to bring their prices down.

However, Walden pointed to solutions that are less far-reaching than what Democrats and Trump have proposed, such as allowing Medicare to negotiate drug prices. Instead, Walden said there could be legislation to speed up the Food and Drug Administration’s approval process for a new competitor to a drug that currently lacks competition.

Walden said that implementing the 21st Century Cures Act, passed by Congress last year, to speed up the FDA’s approval process, is also an important part of the picture.

Trump has gone farther than most Republicans in the past on drug prices, calling for Medicare to negotiate. Trump did not directly call for that policy on Tuesday, though.

Getting any drug pricing legislation through Congress would be a tall task, given how fraught the issue is and the resistance of many Republicans to government action on the issue.

21st Century Cures Act: 4 health industry impacts summarized

http://www.healthcaredive.com/news/21st-century-cures-act-explained/431491/

On Wednesday, the Senate voted 94-5 to pass the long-awaited 21st Century Cures Bill. As it has backing from the current White House administration, President Barack Obama is expected to sign the legislation into law.

The law has been called the “most important bill of the year” by Senator Lamar Alexander (R-TN), as Politico Pulse reported Tuesday. The bill, while bipartisan, is not without controversy. While the House version of the legislation passed swimmingly with a vote of 392-26, the bill did have its share of opponents in the Senate– including Sen. Elizabeth Warren (D-MA) and Sen. Bernie Sanders (I-VT) – who think the bill is too favorable to pharmaceutical companies. Both Sanders and Warren were among the five Senators to vote against the measure.

And as Modern Healthcare’s Merrill Goozner notes in an editorial, it’s likely the true impact of the bill won’t be known right away but will be realized as the years pass. “The final details of the 996-page legislation…weren’t known until five days before it passed,” Goozner wrote.

About three years of work and efforts from 1,400 lobbyists for 400 companies went into the making of this $6.3 billion package. It seeks to deliberately speed medical research and treatments. Because seemingly no healthcare legislation can be a reasonable length (it’s about 90 pages longer than the ACA) and because nothing in healthcare is simple, we’ve summarized some of the notable implications of the bill in four buckets: Health IT, mental health, FDA reform and research and care funding.

House OKs 21st Century Cures bill; Senate votes next week

http://www.fiercehealthcare.com/healthcare/house-passes-landmark-medical-cures-bill-senate-to-vote-next-week?utm_medium=nl&utm_source=internal&mkt_tok=eyJpIjoiTmpNMk1tUmxOekV3TnpZMCIsInQiOiJtUTFHVmlSWVByUWJLZ1JDRjgxaklCNXlaM2hcLzRKRXBpYlE4MFwvV1BydTgyTVJvZjAxUGF5dlFUVVVVSGF6YzdETkNyUGVtY0M1eVV0OXFESWlUNEQ1dFJGeE5hamxLWTFzb1RVRVVGZ1NFPSJ9

congress

Not everyone was on board, however. Rep. Lloyd Doggett (D-Texas) voted against the measure because he said that though the bill attempts to address the need for research funding, it doesn’t guarantee the money: “There may be bipartisan agreement, but there is not a bipartisan advancement.”

He also said the revised version of the bill grants all of big pharma’s “wish lists” and doesn’t tackle rising drug costs. Indeed, Doggett said it was appropriate that the medical cures bill is packed into a larger measure called the Tsunami Warning Bill because people who rely on lifesaving drugs and want to fill a prescription have been “buried in one wave, after another wave, after a giant wave of pharmaceutical price gouging. Whether it’s an EpiPen for a child who is going to have an allergic reaction, whether it’s for insulin for someone who is diabetic and relies on that insulin, whether it’s an oncology drug that costs over $100,000, it is wave after wave of a tsunami of price gouging.”

 

Congress Shouldn’t Pass The 21st Century Cures Act In A Summer Rush

http://healthaffairs.org/blog/2016/07/11/congress-shouldnt-pass-the-21st-century-cures-act-in-a-summer-rush/

Blog_Capitol2

On Saturday June 25, six former FDA commissioners from Democratic and Republican administrations suggested at the Aspen Ideas Festival that Congress make the agency independent of the Department of Health and Human Services — similar to the Securities Exchange Commission, for example. With regulatory purview over products that represent a quarter of the U.S. economy, the group said the FDA is harmed by an unstable federal budget process and persistent political meddling. The group said they would issue a white paper on their proposal for the next administration. That’s another reason why Congress should postpone consideration of these bills until 2017.

Antibiotic Resistance Targeted in 21st Century Cures Act

http://www.medpagetoday.com/PublicHealthPolicy/Washington-Watch/52611?xid=nl_mpt_DHE_2015-07-16&eun=g885344d0r

Bill requires monitoring of financial incentives that encourage antibiotic development.